Abstract

EVALUATION OF AYURVEDIC FORMULATION- NIA/DG/2015/01 IN THE SUSTAINABLE MANAGEMENT OF NEWLY DIAGNOSED STAGE -1 ESSENTIAL HYPERTENSION

Ankita Goyal* and Sudipta Kumar Rath

Abstract

Hypertension is a widely prevalent disease affecting a significant population globally. Hypertension is a major risk factor for the development of cardiovascular disease, cerebrovascular disease causing high rate of mortality and morbidity and renal diseases etc. One in three adults worldwide has high blood pressure. Therefore hypertension is a global health challenge and a lot of effort is devoted to keep the population normotensive. Against the backdrop drug of these facts, the holistic formulation containing arjuna, ashwagandha, jatamansi, shankhpushpi, punarnava was formulated and named NIA/DG/2015/01(trial drug). A single center, randomized, doubleblind, clinical trial (90 days total duration) has been conducted in order to evaluate the action of trial drug–GV (GhanVati) in group A, trial drug – ME (standard extract) in group B of hypertension. The trial drug showed highly significant reduction in Blood pressure in both the groups.

Keywords: Arjuna, ashwagandha, jatamansi, shankhpushpi, punarnava, hypertension.